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Abstract: Extracts of the Floridian marine cyanobacterium Lyngbya cf. confervoides were 
found to deter feeding by reef fish and sea urchins (Diadema antillarum). This antifeedant 
activity may be a reflection of the secondary metabolite content, known to be comprised of 
many serine protease inhibitors. Further chemical and NMR spectroscopic investigation led 
us to isolate and structurally characterize a new serine protease inhibitor 1 that is formally 
derived from an intramolecular condensation of largamide D (2). The cyclization resulted 
in diminished activity, but to different extents against two serine proteases tested. This 
finding suggests that cyanobacteria can endogenously modulate the activity of their 
protease inhibitors. 
Keywords: cyanobacteria; Lyngbya; antifeedant activity; serine protease inhibitors; 
cyclodepsipeptides 
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1. Introduction 
Both marine and freshwater cyanobacteria contain toxic secondary metabolites and are notorious for 
their ability to form extensive blooms. The compounds found in these bloom-forming cyanobacteria 
include the lyngbyatoxins and the hepatotoxic microcystins and cylindrospermopsin [1–6]. Several 
cyanobacterial extracts can reduce feeding by fish, which is thought to be driven by secondary 
metabolite diversity and abundance [69]. However, cyanobacteria also produce a range of protease 
inhibitors with little or no apparent cytotoxicity. One prevalent class found in marine [1013] and 
freshwater [1416] cyanobacteria is comprised of protease inhibitors with a cyclic depsipeptide 
scaffold that contains a 3-amino-6-hydroxy-2-piperidone (Ahp) moiety as a key feature for inhibition 
of certain serine proteases. Since many digestive enzymes such as trypsin and chymotrypsin are serine 
proteases and are inhibited by these compounds, these natural products could function as digestion 
inhibitors [17]. Serine protease inhibitors also co-occur with microcystins and are linked to an 
enhanced toxin activity [18] or thought to upregulate biosynthetic genes [19]. Here we investigate the 
antifeedant activity of a Lyngbya species identified as Lyngbya cf. confervoides (cf. = similar to but not 
the same as; compared to Lyngbya confervoides) [10,20] collected from reefs near Fort Lauderdale, 
Florida, towards natural assemblages of reef fish and the tropical sea urchin Diadema antillarum. This 
cyanobacterium produces a wide array of serine protease inhibitors including lyngbyastatins 4–6 
[21,22], pompanopeptin A [23] and largamides D–G [24]. Extracts of this cyanobacterium deterred 
fish and urchin feeding, which may be linked to the production of these protease inhibitors, however, 
individual compounds have not been tested for their ability to deter feeding. This observed feeding 
deterrent activity led us to thoroughly investigate the natural product chemistry of this cyanobacterium. 
Through rigorous chemical investigation of the crude extracts we identified a new compound, 
largamide D oxazolidine (1), which is an intramolecular condensation product of the serine protease 
inhibitor largamide D (2) (Figure 1). Largamide D oxazolidine (1) exhibited a reduced and differential 
activity against chymotrypsin and elastase, providing evidence for an endogenous mode of 
deactivation or modulation of protease inhibitor activity in this marine cyanobacterium. 
2. Results and Discussion  
2.1. Feeding Experiments 
The extractions yielded a dry weight concentration of 21.15% for the non-polar extract and 6.95% 
for the polar extract. All feeding experiments were conducted at natural concentration by dry weight.  
When tested against a natural assemblage of reef fish in field feeding experiments, where many 
individuals of diverse fish species would feed on food cubes containing cyanobacterial extracts, both 
the polar and non-polar extracts reduced feeding on agar food cubes. The fish consumed 3.58 ± 0.14 
(mean ± SE) agar cubes of the control food, 2.84 ± 0.21 agar cubes of the food containing the polar 
extract, and 1.52 ± 0.29 of the agar cubes that contained the non-polar extract (Figure 2a). There were 
significant differences in the amount of food eaten (n = 19, Friedman’s random block, p < 0.001), with 
less of the polar extract eaten by the fish than the solvent controls and the least amount eaten of the 
food containing the non-polar extract (Student Newman Keuls post-hoc test, p < 0.05). 
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When extracts of L. cf. confervoides were tested against the sea urchin Diadema antillarum, both 
the polar and non-polar extracts reduced urchin feeding. The urchins ate 104.3 ± 6.0 (mean ± SE) 
squares of the control food, 71.0 ± 12.3 squares of the food with the polar extract and 14.3 ± 9.3 
squares of the food with the non-polar extract (Figure 2b). There were statistically different amounts of 
the food consumed (n = 13, Friedman’s random block, p < 0.001) with the solvent control the most 
consumed food, less eaten of the food with the polar extract and the least eaten of the food with the 
non-polar extract (Student Newman Keuls post-hoc test, p < 0.05).  
Figure 1. Structures of largamide D oxazolidine (1) and the parent compound, largamide D (2). 
 
Figure 2. Feeding experiments with the crude extracts of L. cf. confervoides. The bars 
represent the mean amount of food eaten and the error bars are +1 SE. Different letters 
above the bars represent means that are statistically different. (a). Feeding experiments 
with a natural assemblage of reef fish. (b). Feeding experiments with the sea urchin 
Diadema antillarum. 
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Other benthic marine cyanobacteria have also been shown to be chemically defended from marine 
herbivores [69,25]. Ypaoamide, pitipeptolide A, malyngolide and malyngamides A and B are a few 
purified compounds from marine cyanobacteria known to reduce feeding by generalist herbivores such 
as fishes and sea urchins [7,26,27]. More specialized herbivores, such as the sea hare Stylocheilus 
striatus, are usually not deterred by cyanobacterial extracts or compounds [6,9,26], and extracts of L. 
cf. confervoides also did not deter this herbivore relative to controls [28]. However, Stylocheilus 
striatus grew more slowly on L. cf. confervoides relative to L. polychroa, which might be related to the 
presence of serine protease inhibitors in L. cf. confervoides that reduced conversion efficiency of  
this diet [28]. 
2.2. Isolation and Structure Determination of Largamide D Oxazolidine (1) 
The organic extracts from separate samples of the marine cyanobacterium L. cf. confervoides 
collected from two different locations from reefs near Ft. Lauderdale (Florida, USA) were subjected to 
HP-20 fractionation and subsequent HPLC purification to yield either largamide D (2) [24] or a new 
intramolecular condensation product, largamide D oxazolidine (1) (Figure 1). The structure of 2 was 
established by comparison with reported data [24]. Compound 1 displayed a pseudomolecular ion  
[M + Na]
+
 peak at m/z 1236.4745 and an [M + 2 + Na]
+
 isotope peak of similar intensity characteristic 
for bromine, which was consistent with a molecular formula of C56H80BrN9NaO16. The 
1
H and  
13
C NMR spectra (Table 1), featuring typical signals for a peptide, were suggestive of a close analog of 
largamide D (2). A detailed analysis of the 2D NMR (COSY, HSQC, HMBC and TOCSY) spectral 
data of 1 in DMF-d7 clearly supported the structural fragments and enabled the connectivity of the 
depsipeptide along with the side chain, similar to 2. The major chemical shift differences between 1 
and 2 were observed around the Ahp and Thr-1 units. The remaining 
1
H and 
13
C NMR data of 1 in 
MeOH-d4 (Table 1) were in close agreement with the reported data for 2 [24]. Most pronounced were 
the ~11 ppm downfield shifts relative to 2 of the signals for C-6 of the Ahp unit (C 88.6) and C-3 of 
Thr-1 (C 77.4), indicative of alkylation and, to be in agreement with the molecular formula, consistent 
with a formal condensation of Ahp and Thr-1 resulting in an oxazolidine and overall in a fused bicyclic 
system. A 
13
C NMR experiment carried out in a mixture of CD3OD/CD3OH clearly showed doubling 
of signals attributable to carbons attached to the hydroxyl groups in glyceric acid (Ga, C 74.2 and 
65.6). Singlets at C 88.6 (C-6, Ahp) and 77.4 (C-3, Thr-1) supported the absence of exchangeable 
protons in both Ahp and Thr-1 where cyclization has occurred (Figure 3). A second set of resonances 
in a solvent-dependent ratio (1:0.3 in DMF-d7 and 1:0.7 in MeOH-d4) was observed in the NMR 
spectra, indicating the presence of conformers. 
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Table 1. NMR spectral data for the major conformer of largamide D oxazolidine (1) and 
largamide D (2) [24]. 
  1 (DMF-d7) 1 (methanol-d4) 2 (methanol-d4) 
Unit
 a
  H (J in Hz) C COSY HMBC H (J in Hz) C H (J in Hz) C 
Val-1 1  171.4    173.6  174.8 
 2 4.53, m 56.8 H-3, NH 1, 3, 4, 5, 1 (N-
Me-Br-Tyr) 
4.72, m 58.1 4.49, d (7.4) 58.9 
 3 2.32, m 31.1 H-2, H3-4, 
H3-5 
2, 4, 5 2.38, m 32.7 2.15, m 31.8 
 4 0.92, d (7.0) 19.0 H-3 2, 3, 5 0.92, d (7.2) 18.8 0.93, d (6.9) 18.9 
 5 0.86, d (7.0) 17.5 H-3 2, 3, 4 0.89, d (7.2) 18.0 0.99, d (6.9) 19.8 
 NH 6.76, d (8.3)  H-2      
N-Me-
Br-Tyr 
1  169.2    170.9  171.4 
 2 5.71, dd (11.5, 
2.5) 
62.5 H-3a/3b 1 5.75, dd (11.5, 
2.4) 
63.9 5.06, dd (11.5, 3.1) 62.6 
 3a 
 
3.34, dd 
(14.3, 11.5) 
32.4 H-2, H-3b 
H-2, H-3ª 
2, 4 3.28, dd (14.4, 
2.4) 
33.5 3.40, dd (14.6, 
3.1) 
33.8 
 3b 2.89, dd 
(14.3, 2.5) 
   2.84, dd (14.4, 
11.5) 
 2.80, m  
 4  130.5    131.4  130.4 
 5 7.44, d (1.9) 133.8  4, 6, 7, 9 7.32, d (1.2) 134.8 7.34, d (2.0) 134.8 
 6  109.3    111.2  110.8 
 7  153.6    154.7  154.4 
 8 7.03, d (8.2) 116.7 H-9 4, 6, 7, 9 6.83, d (8.3) 117.7 6.87, d (8.2) 117.6 
 9 7.13, dd (8.2, 
1.9) 
129.9 H-8 5, 8 7.02, dd (8.3, 
1.2) 
130.8 7.17, dd (8.2, 2.0) 130.7 
 N-Me 2.92, s 30.8  1, 2, 1 (Thr-1) 2.90, s 31.8 2.87, s 31.2 
Thr-1a 1  169.7    172.0  173.0 
 2 4.04, d (3.4) 59.5 H-3 1, 3, 2 (Ahp), 
H-6 (Ahp) 
3.96, d (2.3) 61.0 4.57, d (6.8) 55.9 
 3 4.36, qd (6.4, 
3.4) 
76.4 H3-4 1, 2, 4 4.38, dq (6.2, 
2.3) 
77.4 3.74, m 66.6 
 4 0.71, d (6.4) 19.4 H-3 2, 3 0.70, d (6.2) 20.5 0.57, d (6.2) 19.6 
Ahpa 2  168.8    170.5  171.3 
 3 4.63, ddd 
(12.4, 8.7, 4.9) 
50.3 H-4a/4b, 
NH 
2, 4, 5, 6 4.63, dd (9.9, 
5.3) 
51.7 4.64, dd (12.4, 6.4) 50.7 
 4a 
 
1.95, m 
 
24.6 H-3, H-4b, 
H-5a/5b 
2, 3, 5, 6 1.97, m 
 
25.3 2.82, m 
 
22.0 
 4b 1.88, m  H-3, H-4a, 
H-5a/5b 
 1.93, m  1.88, m  
 5a 2.38, m 27.9 H-4a/4b, H-
5b, H-6 
3, 4, 6 2.40, m 
 
29.2 2.04, m 
 
30.6 
 5b 1.68, m  
 
 H-4a/4b,  
H-5a, H-6 
 1.66, m  
 
 1.87, m  
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Table 1. Cont. 
 6 5.01, dd 
(8.5, 6.2) 
87.4 H-5a/5b 2, 4, 5 5.03, dd (8.5, 
6.5) 
88.6 5.33, brs 76.9 
 NH 7.22, d (8.7)  H-3 3, 1 (Leu)     
Leu 1  171.7    174.6  174.4 
 2 4.49, m 51.4 H-3a/3b 1, 3 4.58, dd (11.0, 
3.0) 
52.6 4.56, dd (8.5, 3.3) 52.9 
 3a 
 
1.84, m 
 
40.6 H-2, H-3b 
 
1, 2, 4 1.88, m 
 
41.3 1.98, ddd (12.6, 
12.6, 3.3) 
40.2 
 3b 1.47, m  H-2, H-3a  1.47, m  1.55, m  
 4 1.61, m 24.5 H-3a/3b, H3-5, 
H3-6 
2, 3, 5, 6 1.56, m 25.8 1.65, m 25.8 
 5 0.87, d (6.6) 22.9 H-4 4 0.91, d (6.0) 23.8 0.87, d (6.8) 20.0 
 6 0.82, d (6.6) 20.8 H-4 4 0.83, d (6.0) 21.5 0.97, d (6.7) 23.7 
 NH 8.50, d (8.5)  H-2 2, 1 (Thr-2)     
Thr-2 1  169.7    171.1  170.9 
 2 4.92, dd 
(9.0, 1.7) 
55.4 NH 1, 3, 1 (Val-2) 4.72, m 56.7 4.78, d (1.2) 56.3 
 3 5.78, qd 
(6.0, 1.7) 
72.1 H3-4 1, 2, 4, 1 (Val-
1) 
5.64, qd (6.5, 
1.4) 
73.2 5.59, qd (6.5, 1.2) 73.4 
 4 1.33, d (6.0) 16.6 H-3 2, 3 1.30, d (6.5) 17.7 1.36, d (6.5) 18.1 
 NH 8.25, d (9.0)  H-2 2, 1 (Val-2)     
Val-2 1  171.7    173.8  173.9 
 2 4.53, dd 
(8.6, 5.5) 
58.0 H-3, NH 1, 3, 4, 5 4.30, d (7.8) 60.2 4.39, d (7.4) 59.7 
 3 2.17, m 31.2 H-2, H3-4, H3-5 2, 4, 5 2.09, dd (7.8, 
6.8) 
32.0 2.17, m 31.9 
 4 0.90, d (7.0) 18.5 H-3 2, 3, 5 0.94, d (6.8) 18.8 0.98, d (6.9) 18.5 
 5 0.87, d (7.0) 17.5 H-3 2, 3, 4 0.90, d (6.8) 19.4 0.98, d (6.9) 19.8 
 NH 7.76, d (8.6)  H-2 2, 1 (Ala)     
Ala 1  172.0b    174.8  174.4 
 2 4.49, dq 
(9.0, 7.2) 
48.9 H-3, NH 1, 3 4.38, q (7.0) 49.0 4.45, m 49.9 
 3 1.30, d (7.2) 17.0 H-2 1, 2 1.33, d (7.0) 17.8 1.38, d (7.2) 17.6 
 NH 8.26, d (9.0)  H-2 2, 1 (Ahppa)     
Ahppa 1  171.9b    174.1  173.5 
 2 4.52, m 52.6 H-3a/3b, NH 1, 3, 4, NH 4.41, m 54.4 4.46, m 53.9 
 3a 
 
1.89, m 
 
32.4 H-2, H-3b,  
H-4a/4b 
2, 4, 5 1.87, m 
 
32.7 1.91, m 
 
32.6 
 3b 1.73, m  H-2, H-3a,  
H-4a/4b 
 1.69, m  1.73, m  
 4a 
4b 
1.68, m 
1.62, m 
28.2 H-3a/3b, H-4b 
H-3a/3b, H-4a 
2, 3, 5, 6 1.68, m 
1.63, m 
29.0 1.70, m 
1.66, m 
28.8 
 5 2.52, m 34.2 H-4a/4b 3, 4, 6 2.54, m 35.6 2.57, t (7.3) 35.2 
 6  132.6    134.0  133.6 
 7/11 7.03, d (8.3) 129.8 H-8/10 6, 8/10, 9 7.00, d (8.4) 130.4 7.02, dd (8.2, 1.8) 130.2 
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Table 1. Cont. 
 8/10 6.76, d (8.3) 115.2 H-7/11 7/11, 9 6.67, d (8.4, 
2.4) 
116.1 6.70, dd (8.2, 1.8) 115.8 
 9  156.0  7/11, 8/10  156.5  156.2 
 9-OH 9.36, s   8/10, 9     
 NH 7.87, d (7.6)  H-2 1, 2, 1 (Ga)     
Ga 1  172.4    175.4  174.9 
 2 4.11, m 73.5 H-3a/3b 1, 3 4.11, d (3.5) 74.2 4.13, t (3.8) 73.9 
 2-OH c        
 3a 
 
3.76, dd  
(–10.9, 3.5) 
64.7 H-2, H-3b 
 
1, 2 3.78, 2H, d 
(3.5) 
65.6 3.79, 2H, d (3.8) 65.2 
 3b 3.70, dd  
(–10.9, 5.6) 
 H-2, H-3a      
a The initial numbering from largamide D. (2) has been retained for comparison of data [24]. b Can be interchanged.  
c Not observed. 
Figure 3. Expanded regions of the 
13
C NMR spectra (125 MHz) of 1 in CD3OD (bottom 
panel) and 1:1 CD3OD/CD3OH (top) showing peak splitting for carbons attached to the 
free hydroxyl groups. 
 
Based on the comparison of the 
1
H and 
13
C NMR data between 1 and 2 in methanol, we propose the 
same configuration for 1 as reported for largamide D (2) [24] for all unchanged residues. The 
oxazolidine heterocycle formation apparently forced the Ahp unit to adopt a twisted boat-like 
conformation (Figure 4) as evidenced by the ROESY correlations of H-3 with H-5b and H-6, all of 
which had to be in pseudo-axial position on the same face of the ring. This conclusion is consistent 
with the observed coupling constants for H-3 (12.4 and 4.9 Hz) and two relatively large coupling 
constants for H-6 (8.5 and 6.2 Hz) which may be rationalized in this conformation (Figure 4). 
Assuming 1 retained the same configuration at C-3 of the Ahp as in 2—since it is unaffected by 
cyclization—we propose a 3S,6R configuration for Ahp, which is identical to largamide D (2) [24]. 
Furthermore, ROESY correlations from Ahp H-6 to H-2 and H-3 of Thr-1 indicated that they are 
placed on the same side of the oxazolidine ring, providing evidence for a 2S,3S configuration for 
former Thr-1. Since the configuration of Thr-1 has been established as 2S,3R in 2, the configuration at 
C-3 is inverted in compound 1 and represents the only configurational change compared with 
largamide D (2). 
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Figure 4. Selected key ROESY correlations among Ahp and Thr-1 for 1. 
 
The inversion of C-3 configuration (Thr-1) suggests that the OH group of Ahp in 2 may have acted 
as a nucleophile to form the oxazolidine via nucleophilic substitution at C-3 of Thr-1 (rather than the 
opposite way), and this event could have been preceded by addition of an unknown leaving group at  
C-3 or the 3-OH group. Alternatively, Thr-1 could have been dehydrated to a 2-amino-2-butenoic acid 
(Abu) as encountered in lyngbyastatins, also produced by this cyanobacterium, which then served as a 
Michael acceptor, while the chiral environment induced the formation of a single diastereomer, 
compound 1. While it is possible that compound 1 is derived from 2 as an isolation artifact, it is 
tempting to postulate that 1 is a plausible biosynthetic product. In favor of this assumption we note that 
1 was not found in the samples of L. cf. confervoides that yielded largamide D (2) and vice versa from 
the two different collection sites. To the best of our knowledge this fused oxazolidine-containing 
bicyclic system is unprecedented in cyanobacteria but is found in diterpene alkaloids from Spiraea 
japonica [29] and in several polyketide compounds from Actinomycete spp. [3032]. 
2.3. Serine Protease Inhibition Study 
The presence of an Ahp unit is characteristic for many serine protease inhibitors, including 
lyngbyastatins. Largamide D (2) was previously reported to be a moderate chymotrypsin inhibitor [24]. 
We directly compared the activities of compound 1 and largamide D (2) against two serine proteases, 
chymotrypsin and porcine pancreatic elastase (Figure 5, Table 2). Compound 1 exhibited 11-fold and 
33-fold reduced activity against chymotrypsin and elastase, respectively, indicating that the 
condensation of Ahp and Thr-1 considerably deactivated largamide D (2) and to different extents for 
both enzymes tested.  
Figure 5. Effect of compounds 1 and 2 on chymotrypsin and elastase activity. 
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Table 2. Serine protease inhibitory activities (IC50, M) of compounds 1 and 2. 
 Chymotrypsin Elastase 
Largamide D (2) 0.083 ± 0.008 0.045 ± 0.003 
Largamide D oxazolidine (1) 0.928 ± 0.093 1.52 ± 0.08 
2.4. Conclusion 
Marine cyanobacteria produce secondary metabolites that function as chemical defenses against 
consumers. Many of these compounds are serine protease inhibitors that could be responsible for the 
antifeedant activity observed for L. cf. confervoides from Fort Lauderdale reefs. Future studies should 
show the contribution of each serine protease inhibitor or other secondary metabolite produced by this 
particular collection of L. cf. confervoides to the observed antifeedant activity of the extracts. 
Furthermore, the isolation of compound 1 suggests that intramolecular condensation can modulate the 
inhibitory activity. The Ahp moiety is oftentimes critical for protease inhibition, and structural and 
conformational changes involving this unit are expected to affect activity. If indeed biosynthetically 
driven, this represents an endogenous pathway to modulate enzymatic activities. In turn, if this process 
is reversible it could unlock a more potent inhibitor.  
3. Experimental Section 
3.1. General Experimental Procedures 
1
H and 2D NMR spectra for largamide D oxazolidine were acquired in DMF-d7 or MeOH-d4 on a 
Bruker 600 MHz spectrometer using residual solvent signals as the internal standard (δH 8.02, δC 162.3 
for DMF-d7 and δH 3.30 δC 49.0 for MeOH-d4). HSQC experiments were optimized for 
1
JCH = 145 Hz, 
and HMBC experiments were optimized for 
n
JC,H = 7 Hz. 
13
C NMR experiments were performed on a 
Bruker 500 MHz spectrometer (5 mm probe). HRMS data were obtained using an Agilent LC-TOF 
mass spectrometer equipped with an APCI/ESI multimode ion source detector, and low resolution 
mass spectra were obtained on a A3200 Q TRAP LC/MS/MS (hybrid triple quadrupole linear ion trap 
mass spectrometer, Applied Biosystems, USA) with an electrospray ionization (ESI) interface operated 
in positive mode. HPLCbased compound isolation was performed on a Shimadzu LC-20AT 
prominence LC system with peak detection by a Shimadzu SPD-M20A prominence diode  
array detector. 
3.2. Marine Cyanobacterial Samples 
Largamide D oxazolidine (1) was isolated from L. cf. confervoides samples collected at 
approximately 15 m depth from reefs near the Port Everglades Inlet, Fort Lauderdale, Florida, USA 
(26º05.9902′N, 80º05.0184′W) in August 2004 and May and August 2005. Largamide D (2) was 
isolated from L. cf. confervoides samples collected off the coast of Broward County (Fort Lauderdale 
and Pompano Beach, Florida, USA) (26°01.1414’N, 80°05.9973’W; 26°15.134’N, 80°03.908’W) at a 
depth of 7–15 m in July 2004 and August 2005. S. Golubic identified the cyanobacterium [20] and its 
16S rDNA gene sequence has been reported [10,20].  
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3.3. Feeding Experiments 
The fresh L. cf. confervoides collected from Broward County was returned to the laboratory and 
frozen immediately and then freeze-dried. The freeze-dried material was weighed and extracted three 
times in 1:1 ethyl acetate–methanol (non-polar) and then three times in 1:1 ethanol–water (polar). Each 
solvent mixture was left on the cyanobacterium for 24 hours and then exchanged for fresh solvent. 
Each of the three extracts of the same solvents were pooled and dried down under vacuum.  
Fish feeding experiments were conducted with a natural assemblage of reef fish in the field at 
Golden Reef (7 m depth) in Belize (GPS: N 16° 48.575, W 088° 05.138) as previously described [25]. 
This site was selected because the reef fish assemblages were representative of Florida and Caribbean 
coral reefs, our methods were well worked out at this site and large numbers of tropical reef fishes 
would feed during the assay. Feeding experiments were conducted with agar-based food, composed of 
5 g of fish food (Kent Platinum Reef Herbivore), 1.25 g of agar, 1.25 g of carrageenan, and mixed with 
100 mL of boiling water. This mixture was poured warm into 1 cm
3
 molds and allowed to cool. The 
two treatment foods were made by incorporating a natural concentration of the extract (polar or  
non-polar) dissolved in 5 mL of ethanol into the agar mixture just before it was poured. Solvent only  
(5 mL of ethanol) was added to the control food. Most of the ethanol evaporated as the agar cooled and 
gelled. Four agar food cubes were attached with safety pins to each polypropylene rope and offered to 
fish in groups of three ropes (two treatments (one with nonpolar extract and one with polar extract 
incorporated at natural dry mass concentrations) and one control). Nineteen (19) replicate groups of 
three ropes were distributed around the reef. Fish including Thalassoma bifasciatum, Scarus iserti, and 
Acanthurus chirurgus were observed feeding on the food cubes. In the field the number of agar cubes 
eaten was recorded. Results were analyzed with Friedman’s random block test followed by a post-hoc 
multiple comparisons using the Student Newman Keuls method. 
Feeding experiments with the sea urchin Diadema antillarum were conducted in the laboratory at 
Carrie Bow Cay in Belize. Individuals of D. antillarum were collected from the reef flat adjacent to the 
island and maintained individually in 5 gallon buckets with flow through seawater delivered to each 
bucket. The urchins were fed a small amount of Padina sp. before the experiment to ensure that they 
were not starved. The urchins were offered L. cf. confervoides extracts incorporated into artificial food 
that consisted of 2 g of dried and powdered Gracilaria and 1 g of agar. The dried ingredients were 
mixed with 40 mL of boiling water and either the polar or non-polar extract dissolved in 5 mL of 
ethanol or the ethanol alone was added to the agar mixture while it was cooling. The artificial food was 
poured as 2 × 35 cm strips on a sheet of window screen. The window screen was cut so that each 
urchin was offered a 2 × 3 cm strip of each food type, each of which covered 120 squares of the screen. 
The food was left with each urchin for approximately 24 hours. At the end of the experiment the 
number of window screen squares that were no longer covered by the agar food was counted. If the 
food was completely consumed or not consumed at all, that replicate urchin was not included in the 
statistical analysis. The number of squares eaten was recorded for each food type and was statistically 
compared using a Friedman’s random block test, followed by a post-hoc multiple comparisons using 
the Student Newman Keuls method.  
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3.4. Extraction and Isolation 
The extraction and initial fractionation procedures of L. cf. confervoides samples collected from 
Port Everglades Inlet, Fort Lauderdale, Florida, are described in the isolation of tiglicamides [33]. The 
tiglicamide-rich fractions [33] were collected and subjected to repeated semi-preparative reversed-
phase HPLC (Phenomenex Synergi 4 µm Hydro-RP, 250 × 10 mm, 2.0 mL/min; PDA detection at 
200–400 nm) using two sequential linear gradients of MeOH in 0.05% aqueous TFA (60–90% over  
25 min, 90–100% over 10 min) to furnish mixtures containing 1 and tiglicamides A–C. The final 
purification of 1 was achieved by using a Phenomenex Luna Phenyl-hexyl column 250 × 10 mm while 
maintaining the same HPLC conditions described above (1, tR 25.5 min; 6.7 mg). The extraction and 
isolation of L. cf. confervoides samples collected from Broward County and Pompano Beach, Florida, 
are described in the isolation of lynbyastatin 4 [21]. The fraction eluting with 25% aqueous MeOH off 
a C18 Alltech SPE cartridge [21] was then purified by semi-preparative reversed-phase HPLC  
(YMC-Pack ODS-AQ, 250 × 10 mm, 2.0 mL/min; UV detection at 220 and 240 nm) using a  
MeOH–H2O linear gradient (20–100% over 70 min and then 100% MeOH for 10 min), to furnish 
largamide D (2, tR 53.0 min; 2 mg). 
3.5. Largamide D oxazolidine (1) 
Colorless amorphous solid; [α]20D –35 (c 0.1, MeOH), UV (MeOH) max (log ) 204 (4.23), 214 (sh) 
(4.02), 230 (sh) (3.71), 280 (3.22) nm; NMR data, see Table 1; HRESI/APCIMS m/z [M + Na]
+
 
1236.4745, 1238.4742 (ratio 1:1.2, calcd for C56H80
79
BrN9NaO16, 1236.4804; C56H80
81
BrN9NaO16, 
1238.4784).  
3.6. Protease Inhibition Assays 
Elastase assay was assessed using high-purity porcine pancreatic elastase (Elastin Products 
Company, EC134, 135 units/mg). The assay buffer used was 1M Tris-HCl (pH 8.0). Assay buffer  
(79 L), elastase solution (75 g/mL in assay buffer, 5 L) and various concentrations of 1 and 2  
(1 L, dissolved in DMSO) were pre-incubated for 15 min at room temperature in a microtiter plate. 
After this time, 15 L of substrate solution (2 mM N-succinyl-Ala-Ala-Ala-p-nitroanilide in assay 
buffer) was added to each well and the reaction was followed by measuring the absorbance at 405 nm 
every 30 s. Inhibition of chymotrypsin was determined using the -chymotrypsin from bovine 
pancreas (Sigma, C4129, 55 units/mg). The assay buffer was 50 mM Tris-HCl, 100 mM NaCl and  
1 mM CaCl2 (pH 7.8). Assay buffer (39 L), enzyme solution (100 g/mL in assay buffer, 10 L), and 
various concentrations of 1 and 2 (1 L, dissolved in DMSO) were pre incubated for 30 min at room 
temperature before substrate solution (1.5 mM N-succinyl-Gly-Gly-Phe-p-nitroanilide in assay buffer) 
was added. The reaction was followed by measuring the absorbance at 405 nm every 30 s for 30 min. 
For each assay, enzyme activity of each well was calculated using the initial slope of each progress 
curve, expressed as a percentage of the slope of uninhibited reaction. All assays were carried out in 
triplicate at ambient temperature (T = 29 ºC). Molassamide, which also causes complete enzyme 
inhibition, was used as a positive control for inhibition of elastase (IC50 32 nM) and chymotrypsin 
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(IC50 234 nM) [12]. Dose–response curve fitting was done using Xlfit Excel, MathlQ Version 2.2.2 
(IDBS Ltd.). 
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